

CT·RS

Cell Therapies Research & Services



Because every patient has the right to expect treatment

CTRS is a French pharmaceutical company. Since our creation, we have been committed to developing and commercializing treatments for patients with strong unmet medical needs.

Our main focus is rare diseases. Guided by science and research, our ambition is to change academic research program into accessible therapies for patients. We work hand-by-hand with academic structures to develop partnership for relieving and curing patients with rare and severe disorders.





Projects in public and private partnerships



People



Awards

Galién French and International awards, « Pilule d'Or » of Prescrire, Twice honored firm with Prescrire's information awards







CTRS always worked in close collaboration with academic institutions. In more than 15 years, we have signed several partnerships to offer patients access to the therapies the most adapted to their needs.

We are committed to improving the quality of life of patients and particularly involved in :

- hereditary metabolic diseases,
- onco-haematology and immunology,
- gene and cell therapies.





Management Team



Antoine Ferry, MD
Chief Executive Officer



Philippe Maret, PharmD
Qualified Person – Responsible Pharmacist
Managing Director



Christian Cailliot, MD
Medical Director



Bernard Deschamps, MBA
Co-Founder
Managing Director



Virginija Bambalaite, MD
Associate Medical Director



Marco Liguori, MBA
Commercial and Business
Development Director



Marie Fey
Regulatory Affairs Director



Philippe Girault, PharmD
Key Account Manager

Portfolio

PRODUCT	INDICATION	PRE-CLINICAL STAGE	CLINIQUE PHASE	STATUT
Orphacol®	<i>Treatment of two inborn errors in primary bile acid synthesis</i>			UE MA Sept 2013
Neofordex®	<i>In adults, for the treatment of symptomatic multiple myeloma in combination with other medicinal products</i>			UE MA March 2016
Dexliq®	<i>Glucocorticoid</i>			Launch in 2019
Protein Delta 4	<i>Treatment of human immunodeficiency following partially incompatible allogeneic hematopoietic stem cell transplantation</i>			Phase I/ II Q4 2018




Our story is completely linked to our partnership policy: it is one of the essential drivers of our development.

Always looking for new partnerships, we are convinced that it's by pooling our skills that we will be able to develop new therapeutic solutions for patients.

Dedicated in diseases affecting limited patient population, we encourage you to contact us to discuss potential collaborations.

CT·RS

Cell Therapies Research & Services

 63 rue de l'est
92100 Boulogne-Billancourt
FRANCE

 +33 (0)1 41 22 09 70

 ctrs@ctrs.fr

 www.ctrs.fr